How Much Does Zepbound Cost in 2026

Zepbound costs $499 to $1,086.37 at list price and $299 to $699 a month self-pay

Eli Lilly publishes the Zepbound list price as a range rather than a single number: $499 to $1,086.37 per fill, where a fill is a 28-day monthly supply. Lilly defines the list price as the wholesale acquisition cost, the price at which it sells to wholesalers, and states the figure was taken from AnalySource on January 1, 2026. The pricing page does not say which product form sits at each end of the range, so the useful reading is that a pharmacy charging list price for a box of four single-dose pens can charge up to $1,086.37 before any plan, card, or program is applied.

Lilly sells Zepbound in three forms, and the form decides which price paths exist. The single-dose pen is the insured product: it is the only form the $25 savings card covers, and it has no direct-to-patient self-pay price. The 4-count single-dose vial and the single-patient-use KwikPen, which holds four doses, are the self-pay products, sold direct through LillyDirect at fixed prices by dose. The KwikPen is also the only form the Medicare GLP-1 Bridge covers. The table sorts the paths by who qualifies and what each costs on the day this article was checked.

What each Zepbound dose costs through LillyDirect: 2.5 mg to 15 mg in vials or the KwikPen

The Zepbound label starts treatment at 2.5 mg once weekly for 4 weeks, then raises the dose in 2.5 mg increments after at least 4 weeks at each step until a maintenance dose of 5 mg, 10 mg, or 15 mg is reached, with 15 mg as the maximum. The label calls 2.5 mg a starting dose, not a maintenance dose. Because Lilly prices self-pay Zepbound by dose, the answer to how much Zepbound costs depends on where a patient sits in that schedule, and the 10 mg price is not the 2.5 mg price.

Lilly's direct-to-patient prices for the six doses are $299 for 2.5 mg, $399 for 5 mg, $499 for 7.5 mg, and $699 for each of 10 mg, 12.5 mg, and 15 mg. The same schedule applies to a month of four single-dose vials, each 0.5 mL, and to one single-patient-use KwikPen, which holds 2.4 mL and delivers four 0.6 mL doses. One month is 28 days. Lilly notes the direct-to-patient price is not the wholesale acquisition cost, because the product is available at that price only to cash-paying patients. Pen needles for the KwikPen are sold separately, and a valid prescription is required.

A purchase offer lowers the KwikPen price at the four higher doses. Lilly applies a $449 price automatically on the first purchase of a 7.5 mg, 10 mg, 12.5 mg, or 15 mg KwikPen, and keeps it in place only if each refill is bought within 45 days of the delivery or receipt of the previous fill. Miss the 45-day window and the regular price applies again: $499 for 7.5 mg and $699 for 10 mg and above. The offer terms name the KwikPen only. The pages checked for this article state no equivalent offer for vials, so a vial patient at 10 mg should plan on $699 a month unless Lilly's page says otherwise on the day of purchase.

The $25 savings card covers the single-dose pen with commercial insurance, and two more tiers cover excluded plans

The Zepbound savings card has three tiers, and each one is tied to a product form and an insurance status. The headline tier is for patients prescribed the single-dose pen whose commercial drug plan covers it: they pay as little as $25 for a one-, two-, or three-month fill, with Lilly's contribution capped at $100 per one-month fill, $200 per two-month fill, $300 per three-month fill, and $1,300 per calendar year across at most 13 fills. If a plan's copay is $125, the card brings it to $25. If the copay is $600, the card removes $100 and the patient pays $500. The card is a copay reducer, not a price.

The second tier is for patients prescribed the single-dose pen whose commercial plan does not cover it. They pay as low as $499 for a one-month fill, and Lilly defines the savings as the wholesale acquisition cost minus $499. The third tier is for patients prescribed the KwikPen whose commercial plan does not cover the KwikPen: $299 for 2.5 mg with savings capped at $215, $399 for 5 mg capped at $115, $449 for 7.5 mg capped at $65, and $449 for 10 mg, 12.5 mg, or 15 mg capped at $271, for up to 11 fills a year. The 7.5 mg and higher KwikPen prices under this tier are subject to the same 45-day purchase-offer terms as the self-pay price.

All three tiers require a prescription for an approved use consistent with the label, a United States or Puerto Rico address, and an age of 18 or older, and all three exclude anyone enrolled in Medicaid, Medicare, Medicare Part D, Medicare Advantage, Medigap, DoD, VA, TRICARE, or a state prescription assistance program. Patients whose plan uses an alternate funding program that requires them to apply for the manufacturer card as a condition of coverage are also excluded. Every tier expires on December 31, 2026, and Lilly states it can amend or end the card at any time without notice. The GLP-1 insurance coverage guide linked below walks through the prior authorization and step-therapy questions that turn a formulary listing into a $25 fill.

Medicare covers only the Zepbound KwikPen through the GLP-1 Bridge, and sleep apnea goes through the Part D plan

The Medicare GLP-1 Bridge is a temporary CMS demonstration that runs from July 1, 2026 through December 31, 2027. Eligible Part D beneficiaries pay a $50 copay to the pharmacy for a one-month supply, and Medicare.gov and CMS both state that the Bridge covers Zepbound in the KwikPen formulation only. Single-dose Zepbound vials and single-dose pens are excluded. Lilly's own page describes the same arrangement as Zepbound for no more than $50 a month for eligible Part D patients with a prescription for weight management, and adds that it is not a guarantee of coverage.

The $50 does not count toward the Part D deductible or the yearly out-of-pocket limit, the Part D deductible does not apply inside the Bridge, and CMS states there is no low-income subsidy for the Bridge copay. Eligibility runs through CMS clinical criteria and a prior authorization rather than through the plan's ordinary formulary process.

The sleep-apnea indication changes the route. CMS lists type 2 diabetes, moderate to severe obstructive sleep apnea, and noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced fibrosis as Part D-coverable indications, and beneficiaries with those diagnoses are not eligible for the Bridge even if they meet its other criteria. Medicare.gov says the same thing from the beneficiary's side: a person with type 2 diabetes, moderate to severe sleep apnea, or fatty liver disease is ineligible for the Bridge, but their Part D plan might cover the drug. A Zepbound prescription written for obstructive sleep apnea is therefore a plan-coverage question with the plan's own copay and prior authorization rules, not a $50 Bridge fill. A Medicare beneficiary who qualifies for neither path is also excluded from the commercial savings card, which leaves the LillyDirect self-pay schedule.

Telehealth companies prescribe Zepbound; they do not set its price

A telehealth weight-loss company is a medical practice, sometimes with a pharmacy partner. Its clinicians evaluate a patient, write the Zepbound prescription, and route it to a pharmacy, or to LillyDirect if the patient is paying cash. The pharmacy charges the drug price. None of the providers in the Telehealth Ledger catalog publishes a Zepbound medication price below Lilly's direct-to-patient price for the same dose, and none of them can change what Lilly charges.

That is why the Zepbound program page shows figures that look like they describe different products. One provider publishes a monthly price that pays for the consultation only, with the medication billed separately at the pharmacy. Others publish a monthly price that includes the drug, and those figures sit at or above the top of Lilly's list-price range because the provider is passing through a pharmacy charge without a manufacturer program. The live module on this page reads the same catalog and labels each row as medication-included or consultation-only, with the date each price was verified.

The useful question for a telehealth quote is what the fee buys. A consultation-only fee is worth paying when the patient already has a coverage path, a savings card, Bridge eligibility, or a LillyDirect self-pay plan and needs a prescriber. A medication-included fee should be compared against the LillyDirect price for the same dose and form, and against the savings-card copay if the patient has commercial coverage, because the same product is available through those channels at a known price.

Zepbound versus Mounjaro: the same molecule, different labels, different savings cards

Zepbound and Mounjaro are both tirzepatide made by Lilly, and the difference that matters for cost is the label. Zepbound is approved for weight reduction in adults with obesity or overweight with a weight-related condition and for moderate to severe obstructive sleep apnea in adults with obesity. Mounjaro is approved to improve blood sugar in adults and children 10 years and older with type 2 diabetes and to reduce the risk of major cardiovascular events in adults with type 2 diabetes at high risk. Insurers, Medicare, and Lilly's own programs all read the diagnosis on the prescription against those labels.

The savings cards follow the labels. The Mounjaro card lets commercially insured patients with Mounjaro coverage pay as little as $25 for up to a three-month fill, with maximum savings of $150 per one-month fill, $300 per two-month fill, $450 per three-month fill, and $1,950 per calendar year, and it charges $499 for a one-month fill when a commercial plan does not cover Mounjaro. Both cards expire December 31, 2026 and both exclude government-program beneficiaries. Both also require a prescription for an approved use consistent with the product's label, so a Mounjaro prescription written for weight management does not meet the Mounjaro card's terms, and a Zepbound prescription is the one that fits Lilly's weight-management programs.

Two more differences sit on the Medicare and self-pay sides. Type 2 diabetes is a Part D-coverable indication, so a Medicare beneficiary with that diagnosis is routed to the plan's coverage of Mounjaro rather than the GLP-1 Bridge, which covers Zepbound KwikPen only. And the LillyDirect self-pay vial and KwikPen prices in this article are Zepbound prices; the pages checked for this article publish no direct-to-patient price schedule for Mounjaro. The Mounjaro versus Zepbound guide linked below covers the clinical and prescribing differences in more depth.

Compounded tirzepatide is not Zepbound and has no list price, savings card, or Medicare pathway

Compounded tirzepatide is not Zepbound. FDA states that compounded drugs are not FDA approved and that the agency does not review them for safety, effectiveness, or quality before they are marketed. FDA also says a compounded drug might be appropriate only when a patient's medical need cannot be met by an approved drug or the approved drug is not commercially available. FDA declared the tirzepatide injection shortage resolved on December 19, 2024, and ended its enforcement discretion for 503A compounders on February 18, 2025 and for 503B outsourcing facilities on March 19, 2025. Section 503A restricts compounding drugs that are essentially copies of a commercially available drug.

The price structure differs as much as the regulatory status. Zepbound has a published list-price range, a direct-to-patient self-pay schedule by dose, a three-tier savings card, and a Medicare demonstration. Compounded tirzepatide has none of those. Each telehealth company sets its own bundled monthly price with its own compounding pharmacy, and that price usually includes the clinician visit, the vial, and shipping. Because there is no list price, there is no insurance negotiation, no manufacturer copay support, and no Bridge copay.

Comparing the two on price means comparing a LillyDirect figure for a specific Zepbound dose and form against a program fee for a product with a different formulation, concentration, and legal basis. The compounded tirzepatide program page lists current provider prices with their commitment terms and pharmacy disclosures, and the live module on this page shows its rows next to the Zepbound rows so the two structures can be read side by side.

Do not treat a compounded tirzepatide program as a lower-priced version of Zepbound. The product, pharmacy, and regulatory status differ, and the prescribing clinician and dispensing pharmacy must resolve whether compounding is appropriate.

What a year of Zepbound costs on each path

Annual arithmetic shows how far the paths sit apart. A self-pay patient who follows the labeled escalation for one month each at 2.5 mg and 5 mg, spends a month at 7.5 mg, and then holds at 10 mg pays $299, $399, and $499 for the first three months and $699 for the remaining nine on vials, a total of $7,488 for twelve monthly fills at the regular prices. The same schedule on the KwikPen with the $449 purchase offer held through every 45-day refill window is $299, $399, and then $449 for ten months, a total of $5,188. A patient who stays at the 5 mg maintenance dose pays $299 and then $399 for eleven months, or $4,688.

A commercially insured patient whose plan covers the single-dose pen and whose copay is at most $125 pays $25 a month with the savings card, or $300 for twelve fills, until the card expires on December 31, 2026. A patient whose plan excludes the pen pays $499 a month under the card's second tier, or $5,988 a year. An eligible Medicare beneficiary pays $50 a month for the KwikPen through the Bridge, or $600 a year, through December 31, 2027. Twelve fills at the top of Lilly's list-price range come to $13,036.44.

Three costs sit outside these totals. A telehealth or in-person consultation fee applies whenever the prescriber charges one. Pen needles for the KwikPen and any laboratory work the clinician orders are billed separately. And the escalation schedule itself changes the total, because the label allows a clinician to hold a patient at a dose for longer than 4 weeks or to stop at 5 mg or 15 mg rather than 10 mg, and each of those choices changes which LillyDirect price applies. Recheck the current Lilly page before each refill rather than relying on a price from a prior month.